BioSpace News Archive

Invetx, a pioneering animal health biopharmaceutical company, announced a $15 million Series A financing and founding collaborations with WuXi Biologics and AbCellera.

Businesses across China need to secure epidemic supplies such as face masks and disinfectant to re-open factories and offices.

Karius, the world leader in liquid biopsy for infectious diseases, secured $165 million in a new funding round led by SoftBank Vision Fund 21, with additional participation from General Catalyst, HBM Healthcare Investments, and existing investors Khosla Ventures and LightSpeed Venture Partners

GenapSys Inc., the company behind the world’s first highly accurate, affordable, and portable gene sequencer, today announced a new OEM partnership with Twist Bioscience, a company enabling customers to succeed through its offering of high-quality synthetic DNA.

Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at the Cowen & Co. 40th Annual Health Care Conference

Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing novel epigenetic therapies, today provided business and pipeline updates and reported fourth quarter and full year 2019 financial results.

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced the Company has entered into a license grant with Almirall (ALM) for SEYSARA®

G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that the company will present corporate updates at the following investor conferences in March 2020:

NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, today announced that it will report financial results for its 2019 fourth quarter on Friday, February 28, 2020, after market close

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its fourth quarter and full year 2019 financial results and operational highlights before open of U.S. markets on Tuesday, March 3, 2020.